Diagnosis and Management of Canine Hyperadrenocorticism (cHAC)
Abstract views: 69
/ 
PDF downloads: 47
Authors
-
Mohanambal K
Department of Veterinary Medicine, College of Veterinary Science, Rajendranagar, Hyderabad, Telangana, India
-
Satish Kumar K
Department of Veterinary Medicine, College of Veterinary Science, Rajendranagar, Hyderabad, Telangana, India
-
Nagaraj P
Department of Veterinary Medicine, College of Veterinary Science, Korutla, Telangana, India
-
Lakshman M
College of Veterinary Science, Rajendranagar, Hyderabad, Telangana, India
-
Usha Rani M
College of Veterinary Science, Rajendranagar, Hyderabad, Telangana, India
-
Ravi Kumar Y
College of Veterinary Science, Rajendranagar, Hyderabad, Telangana, India
Keywords:
alopecia, ketaconazole, mitotane, polyuriaAbstract
Canine hyperadrenocorticism (cHAC) in an eleven-year-old male dog was diagnosed through battery tests viz., low-dose dexamethasone suppression test, determination of the urine cortisol to creatinine ratio, and dermato-pathological assessment. Symptoms such as increased thirst, excessive appetite, frequent urination, bilateral hair loss, skin thinning, prominent abdominal blood vessels, and distended abdomen were encountered in the present case. Serum biochemistry analysis revealed high levels of ALP, while dermato-pathological examination revealed abnormalities in the epidermis, sweat gland, sebaceous glands, altered hair follicle morphology.A combined therapy approach was employed, consisting of oral tablets containing ketoconazole (10 mg/kg of body weight) and mitotane. The initial mitotane dose was administered at 50 mg/kg of body weight, followed by a maintenance dose of 25 mg/kg of body weight. Theaffected dogdisplayed significant improvement in two months of therapy.
Downloads
References
Behrend, E. N. and Melian, C. Clinical Endocrinology of Companion Animals: Hyperadrenocorticism in dogs. 2013. John Wiley and Sons Ltd., New Jersey, U.S. 1stEdn., pp:43-64.
Bond, R., Hendricks, J., Patterson, K., Stevens, K. and Brooks Brownlie, H. W. (2021). Transverse sectioning in the evaluation of skin biopsy specimens from alopecic dogs. J. Small Anim. Pract.,62: 244-252.
Brown, C. G. and Graves, T. K. (2007). Hyperadrenocorticism: treating dogs. Compendium On Continuing Education For The Practising Veterinarian-North American Edition. 29 (3):132.
Costillo, V., Giacomini, D., Paez-Pereda, M., Stalla, J., Labeur, M., Theodoropoulou, M., Holsboer, F., Grossman, A.B., Stalla, G.K. and Arzt, E. (2006). Retinoic acid as a novel medical therapy for Cushing’s disease in dogs. Endocrinol.,147(9): 4438-4444.
Daniel, E. and Newell-Price, J. D. (2015). Diagnosis of Cushing’s disease. Pituitary., 18: 206-210.
Helm, J. R., Mclauchlan, G., Boden, L. A., Frowde, P. E., Collings, A. J., Tebb, A. J., Elwood, C. M., Herrtage, M. E., Parkin, T. D. and Ramsey, I. K.(2011). A comparison of factors that influence survival in dogs with adrenal dependent hyperadrenocorticism treated with mitotane or trilostane. J. Vet. Intern. Med., 25: 251-260.
Lacroix, A., Feelders, R.A., Stratakis, C.A. and Nieman, L. K. (2015). Cushing’s syndrome. Lancet., 386: 913-927.
Lien, Y. H. and Huang, H. P. (2009). Glycosylated hemoglobin concentrations in dogs with hyperadrenocorticism and/or diabetes mellitus compared to clinically healthy dogs. J. Vet. Sci.,2: 37-41.
Muntener, T., Schuepbach‐Regula, G., Frank, L., Rufenacht, S. and Welle, M. M. (2012). Canine noninflammatory alopecia: a comprehensive evaluation of common and distinguishing histological characteristics. Vet. Dermatol.,23(3): 206-244.
Petersenn, S. and Fleseriu, M. (2015). Pituitary-directed medical therapy in Cushing’s disease. Pituitary.,18: 238-244.
Van der pas, R., De herder, W. W., Hofland, L. J. and Feelders, R. A. (2012). New developments in the medical treatment of Cushing’s syndrome. Endocr. Relat. Cancer., 19: 205-223.
